🚨Trade Alert 🚨 SPRC

🚨Trade Alert 🚨 SPRC͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This biotech stock is trading at mere pennies and could quickly rocket on the NASDAQ…. Greetings All, Although there are no cures for diseases like Alzheimer’s, epilepsy, and Tourette’s syndrome, the focus on treating these diseases has motivated pharma companies to develop innovative treatments. One of the biggest buzzwords in recent years has been “cannabidiol,” also referred to commonly as CBD. The CBD (cannabidiol)-based drug market is growing rapidly, powered by increasing scientific research indicating the therapeutic potential of the ingredient. There are dozens of clinical trials exploring the role of CBD in a wide variety of health areas, including CNS (central nervous system) diseases, pain disorders, cancer, and more. It’s no surprise that pharma companies, small and big, have plowed investments in cannabidiol (CBD). CBD (cannabidiol) is emerging as a promising ingredient in the pharmaceutical industry – where it may have an important therapeutic role across many health areas. Now may be one of the most opportunistic times to have SciSparc Ltd. (NASDAQ: SPRC) on your radar! SPRC’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): - SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease, and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The company had a big announcement this week from the company that could be catalytic… As part of its restructuring plans to unlock value for shareholders, SPRC announced that it has [appointed a new Vice President of Strategy and Business Development,]( Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes works with start-up companies in shaping their business plans and supporting their capital raising rounds as well as identifying new business opportunities. This specialty clinical-stage pharmaceutical company is already led by an experienced team of senior executives and scientists and adding Mr. Baranes to the board could be exponential for further growth. Currently, SPRC has a “STRONG BUY” rating from [Investing.com.]( The legal MJ industry is expected to expand exponentially in the coming years and savvy investors are seeking to profit. Just last October, President Biden announced MJ reforms, which could be the steppingstone for the U.S. to decriminalize the plant on a federal level. In the meantime, as more states in the U.S. and countries decriminalize or legalize the plant and/or its components, there is a growing opportunity on Wall Street to enter the space. This highlights even more why SciSparc (SPRC) a small-cap NASDAQ biotech company trading under $1 a share, could have astronomical upside potential! SPRC has been climbing the ranks of the pharma industry and is revolutionizing the way the world approaches modern medicine! [( SciSparc Ltd. NASDAQ: SPRC A Robust IP Portfolio Repurposing previously approved compounds qualifies SPRC to take advantage of the FDA’s 505 (b)(2) application protocol. This potentially means lower risk, and an expedited development timeline. The result is a robust pipeline of product candidates well positioned to create significant shareholder value into the future. SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system. Currently, the company’s drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain. The company’s research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) andproducts that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable them to generate immediate revenues for the company. Joint Venture Agreement with MitoCareX Bio Ltd. Not long ago, SPRC announced completion of its previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, with MitoCareX Bio Ltd., an Israeli corporation. MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers’ significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers! In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter. Details of the JV agreement can be found [HERE.]( The joint venture [MitoCareX Bio]( focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies. Trustable 3D models of mitochondrial transporters are a valuable tool for the discovery of anti-cancer drugs to help drug producers develop more effective and targeted therapies for cancer. The human mitochondrial carrier family (SLC25A protein family) is the largest group of solute carriers transporting a variety of metabolites, amino acids, nucleotides, and cofactors across the highly selective inner mitochondrial membrane. Consisting of 53 members, transporters of this family are extensively shown to be involved in different types of malignancies such as: cervical, prostate, hepatocellular carcinoma, and breast cancer, among others. However, a major challenge for drug discovery in the field is the very limited amount of solved 3D protein structures (e.g., by x-ray crystallography) that can often ignite computer aided drug discovery campaigns. In addition, these proteins have different functional conformations that may be challenging to be correctly predicted with current machine learning (ML) or AI-based systems, without ad-hoc guidance. To address this challenge, MitoCareX Bio has developed MITOLINE™ - an algorithm used by the company to translate its knowledge concerning specific “hot-spots” within key mitochondrial carriers’ amino acid sequences for the generation of reliable 3D comparative models. According to the company, the generated MITOLINE™ based 3D comparative models of mitochondrial carriers can be used for the study of ligand binding, substrate translocation mechanism, and for the characterization of yet uncharacterized mitochondrial carriers. Joint Pre-Clinical Trial with Clearmind Medicine Inc. SPRC has a joint pre-clinical trial with Clearmind Medicine Inc., (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial has already tested the proprietary combination of SPRC’s CannAmide™ with Clearmind's psychedelic molecule, MEAI, for alcohol consumption.The results of this ground-breaking research show potential for the first dedicated cocaine addiction treatment! You can read about the trial [HERE.]( As part of its ongoing collaboration with Clearmind Medicine Inc., an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”). The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (“PEA”) for the treatment of depression. Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. An additional six patent applications have been filed for the combination of SciSparc's PEA and lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4 methylenedioxymethamphetamine (MDMA), ibogaine and ketamine. In Summary… While the usage of cannabis has been popular in recent years, it’s only very recently that we are discovering the rare cannabinoid potential. Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies [have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia](. Psychedelics have also become an increasingly popular area for medical research and studies. A report by [Market Digits]( estimates that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020! With so many people around the world suffering from conditions that have no known cure, it’s become vital that research and more is done to help these people and the symptoms they endure as a result of these conditions. With strong leadership, exciting joint ventures, as well as a growing $4M+ market cap SciSparc Ltd. (NASDAQ: SPRC) looks positioned to shine bright in the market and could be at SUPREME VALUE right now. This may be one of the most exciting small-cap biotech stocks of 2023! START YOUR RESEARCH! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in SPRC. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding SPRC with a start date of 6/01/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042